Drug Kinetics Clinical Trial
Official title:
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib in Healthy Adults
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib in Healthy Adults
| Status | Not yet recruiting |
| Enrollment | 24 |
| Est. completion date | June 30, 2025 |
| Est. primary completion date | September 30, 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 19 Years to 55 Years |
| Eligibility | Inclusion Criteria: 1. Healthy adults aged 19 or older and 55 or younger at the time of screening tests. 2. Men weigh more than 55 kg and women weigh more than 50 kg. 3. Those who have a body mass index of 18.5 kg/m2 or more and less than 27.0 kg/m2. ? Body mass index (body mass index, kg/m2) = Weight (kg)/[Height (m)]2 4. If participants are a woman, participants must apply to one of the following. - Menopause (no natural menstruation for at least 2 years) - Surgical infertility (hysterectomy or bilateral oophorectomy, tubal ligation, or other infertility) 5. If a male has sex with a female of childbearing age, he/she must agree to use contraception* until at least 28 days after the clinical trial period and the final administration of the clinical trial drug and not to donate sperm. *Contraception: Use a combination of vasectomy, intrauterine device, tubal ligation and blocking contraception (male condom, female condom, cervical cap, contraceptive septum, sponge, etc.) or use a combination of two or more blocking contraception when using a biocidal agent. 6. A subject who has fully understood and received sufficient explanation of this clinical trial and has voluntarily decided to participate and agreed in writing to comply with the precautions. Exclusion Criteria: 1. A person with a history of clinically significant hepatobiliary system (severe hepatic disorder, hyperbilirubinemia, pancreatitis, etc.), kidney (severe renal disorder, acute renal failure, etc.), urethral disorder, nervous system, immune system, respiratory system, endocrine system, cardiovascular system (myocardial infarction, congestive heart failure, unstable angina, bradycardia, long QT syndrome, torsade de points, etc.), blood, tumor, urinary system, psychiatric disorder, or medical history. 2. Those with a history of gastrointestinal diseases (Crohn's disease, ulcerative colitis, etc.) or surgery (except for simple appendectomy or hernia surgery) that can affect the absorption of drugs. 3. A person who has a history of clinically significant hypersensitivity reactions or allergies to drugs or additives (Yellow 5, Sunset Yellow FCF), including ingredients (Radotinib) of clinical trial drugs. 4. A person who was judged to be inappropriate as a test subject in a screening test conducted within 28 days prior to administration of a clinical drug (examination, blood pressure, 12-lead electrocardiogram, physical examination, clinical laboratory examination, etc.). - In the case of > 1.5 times the upper limit of AST and ALT normal range in the blood - In the case of > 1.5 times the upper limit of Total bilirubin normal range in the blood - Estimated Global Film Rate (eGFR) <60 mL/min/1.73 m2 using the Modification of Diet in Regular Disease (MDRD) formula - Serum test (hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test, syphilis test) result are positive factors - QTcF > 480 msec on electrocardiogram - After resting for at least 5 minutes, those who showed a value corresponding to systolic blood pressure>150 mmHg or <90 mmHg, diastolic blood pressure>100 mmHg or <50 mmHg in the vital signs measured at the seat 5. A person who shows suspected symptoms of acute illness (chilliness, fever, diarrhea, stomatitis, redness, infectious symptoms, etc.) at the time of screening tests. 6. A person who has a history of drug abuse or has tested positive in a urine drug screening test within one year of screening. 7. If the tester determines that the following drugs, excluding topical drugs without significant systemic absorption, may affect this test or affect the safety of the test subject within the relevant period. - In the case of taking general medicines including health foods and vitamin preparations within 7 days prior to the first administration of clinical trial drugs - In the case of taking a prescription drug or herbal medicine within 14 days prior to the first administration date of the clinical trial drug - A person who has administered a CYP3A4 inhibitor (ketoconazole, itraconazole, erythromycin, clarithromycin, etc.) or a CYP3A4 inhibitor (dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, St. John's short [hypericum perforatum], etc.) within 30 days prior to the first administration of clinical trial drug - A person who has administered antiarrhythmic drugs (amiodarone, disopyramid, propofol, quinidine, totalol, etc.) or other drugs that can extend the QT interval (chloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin, bepridil, pimozide, etc.) within 30 days prior to the first administration of clinical trial drug - A person who has received a P-glycoprotein derivative such as ritonavir within 30 days prior to the first day of administration of a clinical trial drug 8. A person who has consumed grapefruit-containing food within 7 days prior to the first administration date of clinical trial drugs or cannot be prohibited from taking it during the clinical trial period. 9. A person who continuously smoked excessively or consumed caffeine or alcohol (caffeine: >5 cups/day, alcohol: >210 g/week, tobacco: >10 g/day) or who cannot stop smoking, caffeine and alcohol consumption during each hospitalization period. 10. A person who participated in another clinical trial (including a bioequivalence test) within 180 days prior to the first administration date of the clinical trial drug and received the clinical trial drug (in the case of biological agents, it may be based on an extended period considering a half-life). 11. A person who donated whole blood within 60 days prior to the first administration date of clinical trial drugs or donated component blood within 30 days. 12. A person who received a blood transfusion within 30 days prior to the first administration date of the clinical trial drug. 13. Pregnant or lactating female at the time of screening tests. 14. A person who determines that the tester is inappropriate to participate in clinical trials due to other reasons. |
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | Severance Hospital | Seoul |
| Lead Sponsor | Collaborator |
|---|---|
| Il-Yang Pharm. Co., Ltd. |
Korea, Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Cmax(Maximum concentration of drug in plasma) | Pre-dose(0 hour), after dose 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 32 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours | ||
| Primary | AUClast(Area under the plasma drug concentration-time curve to last concentration) of Radotinib | Pre-dose(0 hour), after dose 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 32 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours | ||
| Secondary | AUCinf(Area under the plasma drug concentration-time curve from 0 to infinity) of Radotinib | Pre-dose(0 hour), after dose 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 32 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours | ||
| Secondary | Tmax(Time to maximum plasma concentration) of Radotinib | Pre-dose(0 hour), after dose 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 32 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours | ||
| Secondary | t1/2(Terminal elimination half-life) of Radotinib | Pre-dose(0 hour), after dose 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 32 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours | ||
| Secondary | Vd/F(Apparent volume of distribution), CL/F(Apparent clearance) of Radotinib | Pre-dose(0 hour), after dose 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 32 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours | ||
| Secondary | Cmax of Radotinib metabolites(M1, M2) | Pre-dose(0 hour), after dose 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 32 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours | ||
| Secondary | Tmaxof Radotinib metabolites(M1, M2) | Pre-dose(0 hour), after dose 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 32 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours | ||
| Secondary | t1/2, metabolic ratio(AUClast of metabolite/AUClast of Radotinib) of Radotinib metabolites(M1, M2) | Pre-dose(0 hour), after dose 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 32 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00538798 -
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203
|
Phase 1 | |
| Recruiting |
NCT02575755 -
A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women
|
Phase 4 | |
| Completed |
NCT05366283 -
Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation
|
Phase 1 |